Apolipoprotein News and Research

RSS

Vermillion, Quest Diagnostics enter agreement to launch OVA1 IVDMIA assay in India

Vermillion, a molecular diagnostics company, today announced that it has signed an agreement with Quest Diagnostics to make OVA1 available in India. The companies are targeting a launch in the second quarter of 2011. Additionally, at the International Gynecologic Cancer Society (IGCS) regional meeting held in New Delhi April 2-3, 2011, Dr. Fred Ueland presented data demonstrating the high sensitivity for ovarian malignancy of OVA1 in combination with ultrasound.

From Quest Diagnostics 4 Apr 2011

Researchers identify four new genes linked to Alzheimer's disease

In the largest study of its kind, researchers from a consortium of 44 universities and research institutions in the United States, including Rush University Medical Center, identified four new genes linked to Alzheimer's disease. Each gene individually adds to the risk of having this common form of dementia later in life.

4 Apr 2011

Discovery of 4 new genes associated with Alzheimer's

In the largest study of its kind, researchers from a consortium led by the University of Pennsylvania School of Medicine, Boston University School of Medicine and the University of Miami identified four new genes linked to Alzheimer's disease. Each gene individually adds to the risk of having this common form of dementia later in life. These new genes offer a portal into what causes Alzheimer's disease and is a major advance in the field.

3 Apr 2011

New Neurotez method can predict genetic factors responsible for AD

The new Neurotez method will allow for an elegant and rapid way to screen a large number of patient-derived samples and measure the degree of confidence in predicting a subject's risk for getting Alzheimer's disease, based on her/his TOMM40/APOE haplotype.

22 Mar 2011

FDA accepts Arisaph's ARI-3037MO IND for phase I human clinical trial

Arisaph Pharmaceuticals, Inc., a privately held drug discovery biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted the Company's recently submitted Investigational New Drug application to evaluate ARI-3037MO in a phase I human clinical trial in healthy volunteers.

22 Mar 2011

HDL cholesterol structure finding could help explain cardioprotective effects

University of Cincinnati researchers have determined the structure of human HDL cholesterol and say the finding could help explain how this "fat packet" protects against cardiovascular diseases, including heart attack and stroke.

14 Mar 2011

Psychosocially hazardous neighborhood may influence cognitive function in older age

Residing in a psychosocially hazardous neighborhood is associated with worse cognitive function in older age for persons with the apolipoprotein E ε4 allele, according to a report in the March issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

9 Mar 2011

Increased alcohol consumption leads to multiple cardiovascular outcomes

A summary paper on the effects of alcohol consumption on biologic mechanisms associated with coronary heart disease provides an excellent review of a large number of intervention studies in humans.

8 Mar 2011

USPTO issues two patents to VIRxSYS SMaRT RNA platform technology

VIRxSYS Corporation, a privately-held biotechnology company with proprietary RNA payload and lentiviral vector delivery platform technologies, today announced that the United States Patent and Trademark Office has issued the Company two patents for its SMaRT RNA platform technology, capable of reprogramming or repairing genes to create, increase or change protein expression.

18 Feb 2011

Diet high in Omega 3 oils benefits at risk Alzheimer's disease patients

Scientists today agree that there are five molecules that are known to affect or cause Alzheimer's disease, which plagues an estimated five million Americans. The potency of these molecules is linked to environmental factors such as diet and lifestyle.

16 Feb 2011

How cocoa in chocolate reduces risk of heart disease

In time for the chocolate-giving and chocolate-noshing fest on Valentine's Day, scientists are reporting discovery of how this treat boosts the body's production of high-density lipoprotein cholesterol (HDL) - the "good" form of cholesterol that protects against heart disease.

8 Feb 2011

New molecular player responsible for regulation of appetite and metabolism

A study by researchers at Mayo Clinic's campus in Florida and Washington University School of Medicine adds a new twist to the body of evidence suggesting human obesity is due in part to genetic factors. While studying hormone receptors in laboratory mice, neuroscientists identified a new molecular player responsible for the regulation of appetite and metabolism.

28 Jan 2011

Lipoprotein receptor LRP1 also regulates food intake and energy balance in central nervous system: Study

12 Jan 2011

Isis commences ISIS-APOCIIIRx Phase 1 trial in hypertriglyceridemia

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-APOCIIIRx, an antisense drug designed to lower triglycerides to treat a variety of diseases associated with elevated triglycerides. Hypertriglyceridemia, a condition characterized by elevated levels of triglycerides, is an independent risk factor for cardiovascular disease and is a component of numerous cardiovascular and metabolic diseases, including metabolic syndrome.

21 Dec 2010

Gene variant affects brain function long before brain begins accumulating amyloid: Study

People with a known, high risk for Alzheimer's disease develop abnormal brain function even before the appearance of telltale amyloid plaques that are characteristic of the disease, according to a new study.

17 Dec 2010

New clues into mechanisms underlying antiphospholipid syndrome

Thanks to findings by UT Southwestern Medical Center researchers, individuals with a potentially life-threatening condition predisposing them to blood clots, or thrombosis, might someday receive therapy to prevent the condition.

4 Dec 2010

Amarin reports top-line results from AMR101 Phase 3 trial for treatment of high triglycerides

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from the MARINE study, its first Phase 3 clinical trial of lead drug candidate AMR101.

29 Nov 2010

Physical activity may protect high-risk individuals from cognitive decline: Study

Physical activity promotes changes in the brain that may protect high-risk individuals against cognitive decline, including development of Alzheimer's disease, according to a new study done at the University of Wisconsin-Milwaukee (UWM).

19 Nov 2010

Gene transfer reduces and stabilizes plaque and decreases inflammation

A plaque-fighting gene - studied in various forms by researchers at the Cedars-Sinai Heart Institute for 18 years - has now been transferred intravenously to lab mice bred to model atherosclerosis (clogged arteries) in humans. Studies show the gene transfer reduced and stabilized plaque and decreased inflammation, key factors in cutting the risk of heart disease.

18 Nov 2010

Researchers report results from Phase III DEFINE study for coronary heart disease

Researchers today presented results from the Phase III DEFINE (Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib) study with Merck's investigational CETP inhibitor, anacetrapib. In the trial of 1,623 patients with coronary heart disease (CHD) or CHD risk equivalents, anacetrapib showed no significant differences from placebo in the primary safety measures studied.